Donovan Maust

Dr. Donovan Maust

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
DMDonovan Maust
Donovan Maust
HKHyungjin Myra Kim
Hyungjin Myra Kim
LSLisa S. Seyfried
Lisa S. Seyfried
CCClaire Chiang
Claire Chiang
JKJanet Kavanagh
Janet Kavanagh
HKHelen C. Kales
Helen C. Kales
Individual clinical trials and meta-analyses have suggested modest benefit from some antipsychotic agents over placebo for the treatment of psychosis and aggression in patients with dementia1-3 and that these symptoms may return when a medication is discontinued.4 Potential harms anticipated with use of these medications include known adverse effects such as metabolic changes and extrapyramidal symptoms.1,5,6 However, evidence pooled across randomized, placebo-controlled trials (RCTs) of atypical antipsychotics, such as risperidone and olanzapine, demonstrated an increased risk of cerebrovascular adverse events for which the US Food and Drug Administration (FDA) issued a warning in 2003.7 Subsequent analyses of published and unpublished clinical trial data on atypical antipsychotics by the FDA and a meta-analysis of 15 RCTs by Schneider et al8 demonstrated an increased mortality risk. In April 2005, the FDA9 issued a black box warning that the use of atypical antipsychotics leads to increased all-cause mortality when used for behavioral disturbances in patients with dementia. Additional observational analyses10,11 have demonstrated that first-generation antipsychotic agents confer an even higher mortality risk than do the atypical agents, leading to another FDA12 black box warning in 2008. However, at the time the warnings were issued, the available evidence described class-wide effects on mortality without clear delineation of the risks associated with individual medications.

25 November 2022 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
LLLianlian Lei
Lianlian Lei
ALAmanda N. Leggett
Amanda N. Leggett
DMDonovan Maust
Donovan Maust

9 March 2021 in JAMA
Verified
Journal Article
Open access
PDF file
DMDonovan Maust
Donovan Maust
JSJulie Strominger
Julie Strominger
HKH. Myra Kim
H. Myra Kim
KLKenneth M. Langa
Kenneth M. Langa
JBJulie P. W. Bynum
Julie P. W. Bynum
SMSteven C. Marcus
Steven C. Marcus
Quiz Ref ID The number of persons with dementia in the US is projected to grow to 50 million people by 2050,1 but the US health care system is poorly equipped to deal with these patients and their complex medical and psychosocial needs.2 Although memory impairment is the cardinal feature of dementia, behavioral and psychological symptoms (eg, apathy, delusions, agitation) are common during all stages of illness and cause significant caregiver distress.3,4 Despite limited high-quality evidence of efficacy for pharmacological treatment,5 clinicians regularly prescribe psychotropic medications to community-dwelling persons with dementia6 in rates that far exceed use in the general older adult population.7

1 May 2018 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
DMDonovan Maust
Donovan Maust
HKH. Myra Kim
H. Myra Kim
CCClaire Chiang
Claire Chiang
HKHelen C. Kales
Helen C. Kales
The behavioral and psychological symptoms of dementia are found in patients with all types and stages of dementia and occur in clusters or syndromes such as psychosis (delusions and hallucinations), agitation, aggression, and disinhibition.1-3 Nonpharmacologic interventions—better stated as behavioral and environmental interventions—are recommended by numerous guidelines, medical organizations, and expert groups as the preferred first-line treatment,4-7 although they have largely not been translated into routine clinical practice.8 Despite the fact that no drugs have been approved by the US Food and Drug Administration (FDA) for the behavioral and psychological symptoms of dementia, the current mainstay of treatment is the off-label use of psychotropic medications.9,10 Of such agents, atypical antipsychotics have the strongest base of evidence, although their benefits are moderate at best and they are associated with a significant increase in the risk of stroke and mortality.11,12 Given the concerns regarding mortality, the FDA issued black box warnings for atypical antipsychotics in 2005 and for conventional antipsychotics in 2008.

26 April 2017 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
DMDonovan Maust
Donovan Maust
FBFrederic C. Blow
Frederic C. Blow
IWIlse R. Wiechers
Ilse R. Wiechers
HKHelen C. Kales
Helen C. Kales
SMSteven C. Marcus
Steven C. Marcus
To describe how use of antidepressants, benzodiazepines, and other anxiolytic/sedative-hypnotics among older adults (age ≥ 65 years) has changed over time among visits to primary care providers and psychiatrists. Data were from the National Ambulatory Medical Care Survey (years 2003-2005 and 2010-2012), a nationally representative cross-section of outpatient physician visits. Analysis focused on visits to primary care providers (n = 14,282) and psychiatrists (n = 1,095) at which an antidepressant, benzodiazepine, or other anxiolytic/sedative-hypnotic was prescribed, which were stratified by demographic and clinical characteristic (including ICD-9-CM diagnosis) and compared across study intervals. Odds of medication use were calculated for each stratum, adjusting for demographic and clinical characteristics. The visit rate by older adults to primary care providers where any of the medications were prescribed rose from 16.4% to 21.8% (adjusted odds ratio [AOR] = 1.43, P < .001) while remaining steady among psychiatrists (75.4% vs 68.5%; AOR = 0.69, P = .11). Primary care visits rose for antidepressants (9.9% to 12.3%; AOR = 1.28, P = .01) and other anxiolytic/sedative-hypnotics (3.4% to 4.7%; AOR = 1.39, P = .01), but the largest growth was among benzodiazepines (5.6% to 8.7%; AOR = 1.62, P < .001). Among patients in primary care, increases primarily occurred among men, non-Hispanic white patients, and those with pain diagnoses as well as those with no mental health or pain diagnoses. From 2003 to 2012, use of the most common psychotropic medications among older adults seen in primary care increased, with concentration among patients with no mental health or pain diagnosis. As the population of older adults grows and receives mental health treatment in primary care, it is critical to examine the appropriateness of psychotropic use.

18 February 2016 in International Journal of Geriatric Psychiatry
Verified
Journal Article
Closed access
PDF file
DMDonovan Maust
Donovan Maust
KLKenneth M. Langa
Kenneth M. Langa
FBFrederic C. Blow
Frederic C. Blow
HKHelen C. Kales
Helen C. Kales